title: Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data-authors' response.
authors.affiliation: Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Microbiology, Health Sciences Centre, MS-673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada ggzhanel@pcs.mb.ca.
authors.forename: George G
authors.initials: GG
authors.lastname: Zhanel
authors.affiliation: Established Products Clinical Development, Pfizer Inc., New York, NY, USA.
authors.forename: Kevin D
authors.initials: KD
authors.lastname: Wolter
authors.affiliation: Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Microbiology, Health Sciences Centre, MS-673-820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada.
authors.forename: James A
authors.initials: JA
authors.lastname: Karlowsky
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology*; D013296:Streptococcus pneumoniae
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin